Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE).

Suda, Katie J, Alfredo Traversa, Ursula Patel, Linda Poggensee, Margaret A Fitzpatrick, Geneva M Wilson, and Charlesnika T Evans. 2023. “Uptake in Newly Approved Antibiotics Prescribed to Patients With Carbapenem-Resistant Enterobacterales (CRE).”. Infection Control and Hospital Epidemiology 44 (4): 674-77.

Abstract

We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.

Last updated on 05/20/2025
PubMed